What is Wedbush's Forecast for Rezolute Q3 Earnings?

Key Points

• Wedbush forecasts that Rezolute will report a Q3 2026 earnings estimate of ($0.27) per share, with the stock receiving an Outperform rating and a price target of $12.00.
• The recent quarterly earnings release showed Rezolute missed analysts' expectations with an EPS of ($0.26), which is $0.03 below the consensus estimate.
• Institutional investors own 82.97% of Rezolute's stock, indicating significant institutional confidence, as several firms increased their stakes in the company in the second quarter.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Wedbush issued their Q3 2026 earnings estimates for shares of Rezolute in a research report issued on Thursday, September 18th. Wedbush analyst Y. Zhong expects that the company will earn ($0.27) per share for the quarter. Wedbush has a "Outperform" rating and a $12.00 price target on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share. Wedbush also issued estimates for Rezolute's FY2030 earnings at $0.71 EPS.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Wednesday, September 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.03).

A number of other equities analysts have also recently issued reports on RZLT. BTIG Research reiterated a "buy" rating and set a $17.00 price objective on shares of Rezolute in a research report on Thursday. Maxim Group upped their price target on shares of Rezolute from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday. Finally, HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of Rezolute in a research report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, Rezolute has a consensus rating of "Buy" and an average price target of $14.40.

Rezolute Price Performance

RZLT stock opened at $7.70 on Monday. The company has a 50 day simple moving average of $6.62 and a 200 day simple moving average of $4.74. The stock has a market cap of $699.24 million, a price-to-earnings ratio of -7.94 and a beta of 0.02. Rezolute has a 1 year low of $2.21 and a 1 year high of $8.81.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RZLT. Federated Hermes Inc. boosted its stake in Rezolute by 24.4% during the second quarter. Federated Hermes Inc. now owns 14,034,712 shares of the company's stock worth $62,595,000 after acquiring an additional 2,755,385 shares in the last quarter. Rosalind Advisors Inc. bought a new position in Rezolute during the second quarter worth $7,766,000. Geode Capital Management LLC boosted its stake in Rezolute by 201.7% during the second quarter. Geode Capital Management LLC now owns 1,711,043 shares of the company's stock worth $7,633,000 after acquiring an additional 1,143,834 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Rezolute by 56.4% in the second quarter. Marshall Wace LLP now owns 2,886,481 shares of the company's stock valued at $12,874,000 after buying an additional 1,041,234 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in shares of Rezolute by 77.4% in the second quarter. Nantahala Capital Management LLC now owns 2,291,395 shares of the company's stock valued at $10,220,000 after buying an additional 1,000,000 shares in the last quarter. 82.97% of the stock is owned by institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.